Novartis India Ltd is set to enter a new phase of growth following the acquisition of the Swiss parent company’s 70.68% stake by private equity firm ChrysCapital. The transaction marks a significant ownership transition, paving the way for the company to adopt a new corporate identity, appoint a new leadership team and strengthen its presence in India’s branded pharmaceuticals market. The acquisition follows Novartis AG’s decision in 2024 to review the future of its India-listed subsidiary. Announced earlier this year, the deal was valued at ₹1,446 crore.
ChrysCapital Makes First Majority Investment in Indian Pharma
With this acquisition, ChrysCapital has made its first majority-controlled investment in India’s pharmaceutical sector. The private equity firm said Novartis India will adopt a new name and corporate identity, reflecting its transition from the Swiss pharmaceutical group to an independently managed company backed by private equity. ChrysCapital aims to transform the business into a leading branded generics platform for the Indian pharmaceutical market while building on the company’s strong legacy and established market presence.
New Leadership Team to Drive Next Growth Phase
As part of the ownership transition, Novartis India has appointed Dr. Vikas Gupta as Chief Executive Officer and Managing Director. The company has also strengthened its Board by appointing Ramesh Ramadurai, Suchita Sharma and Shashank Sinha as Independent Directors. Initially, the business will continue leveraging its existing contract manufacturing partnerships while gradually building its own operational capabilities.
Management Focuses on Portfolio Expansion
Dr. Vikas Gupta, Chief Executive Officer and Managing Director, said the company intends to build on its decades-long legacy of scientific excellence and physician confidence. He noted that, with ChrysCapital’s support, the company now has the resources and strategic focus to expand its product portfolio, reach more patients and accelerate long-term growth while preserving the values that have defined the organisation over the years.
ChrysCapital Sees Long-Term Value Creation
Kshitij Sheth, Managing Director at ChrysCapital Advisors, said the company’s established brands, strong market reputation and trusted legacy provide a solid foundation for sustainable long-term value creation. He added that ChrysCapital will work closely with the management team to unlock new growth opportunities and strengthen the company’s position in India’s rapidly evolving pharmaceutical market.
New Chapter Begins for Novartis India
With new ownership, experienced leadership and a planned corporate rebranding, Novartis India is poised to begin a new chapter focused on expanding its branded generics business. As reported by thehindubusinessline.com, backed by ChrysCapital’s investment and strategic direction, the company aims to leverage its legacy brands while pursuing sustainable growth in one of the world’s fastest-growing pharmaceutical markets.
